Clinical trial
Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed…
NCT00097409 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00097409 |
|---|---|
| Title | Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer |
| Official title | A Phase II, Open-Label Study of Ispinesib in Subjects With Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Ispinesib |
| Enrollment | 35 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 24, 2004 |
| Last update posted | Oct 4, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: